Hansoh Pharma's AMEILE (almonertinib) Receives Marketing Authorization in China for Second-line Treatment for Patients With EGFR T790m-mutation Non-small Cell Lung Cancer - BioSpace

Hansoh Pharma's AMEILE (almonertinib) Receives Marketing Authorization in China for Second-line Treatment for Patients With EGFR T790m-mutation Non-small Cell Lung Cancer  BioSpace